Literature DB >> 28826520

Small Molecule PET Tracers in Drug Discovery.

David J Donnelly1.   

Abstract

The process of discovering and developing a new pharmaceutical is a long, difficult, and risky process that requires numerous resources. Molecular imaging techniques such as PET have recently become a useful tool for making decisions along a drug candidate's development timeline. PET is a translational, noninvasive imaging technique that provides quantitative information about a potential drug candidate and its target at the molecular level. Using this technique provides decisional information to ensure that the right drug candidate is being chosen, for the right target, at the right dose within the right patient population. This review will focus on small molecule PET tracers and how they are used within the drug discovery process. PET provides key information about a drug candidate's pharmacokinetic and pharmacodynamic properties in both preclinical and clinical studies. PET is being used in all phases of the drug discovery and development process, and the goal of these studies are to accelerate the process in which drugs are developed.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28826520     DOI: 10.1053/j.semnuclmed.2017.05.006

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  4 in total

Review 1.  Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.

Authors:  Pradeep J Nathan; Geor Bakker
Journal:  Psychopharmacology (Berl)       Date:  2020-01-04       Impact factor: 4.530

Review 2.  Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.

Authors:  Fabian Krutzek; Klaus Kopka; Sven Stadlbauer
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

3.  [18F]BIBD-181: A Novel Positron Emission Tomography Tracer Specific for Synaptic Vesicle Glycoprotein 2A.

Authors:  Zeng Jiang; Xuebo Cheng; Hualong Chen; Wei Zheng; Yuli Sun; Ziyue Yu; Tingyu Yang; Lu Zhang; Di Fan; Zhihao Yang; Yajing Liu; Lin Ai; Zehui Wu
Journal:  ACS Med Chem Lett       Date:  2022-03-30       Impact factor: 4.632

4.  Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.

Authors:  Kevin P Maresca; Jianqing Chen; Divya Mathur; Anand Giddabasappa; Adam Root; Jatin Narula; Lindsay King; David Schaer; Jonathan Golas; Keith Kobylarz; Edward Rosfjord; Edmund Keliher; Laigao Chen; Sripad Ram; Eve H Pickering; James S Hardwick; Paul A Rejto; Amira Hussein; Ohad Ilovich; Kevin Staton; Ian Wilson; Timothy J McCarthy
Journal:  Mol Imaging Biol       Date:  2021-06-18       Impact factor: 3.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.